Key result
Ticagrelor raises fazamorexant peak concentration ~14% without causing a clinically meaningful interaction.
Why the study?
Fazamorexant demonstrated in vitro metabolism via CYP3A4, prompting investigation into the effects of CYP3A4 inhibitors on its pharmacokinetics, safety, and tolerability.
Does co-administration of ticagrelor alter the pharmacokinetics of fazamorexant in healthy subjects?
Does co-administration of ticagrelor alter the pharmacokinetics of fazamorexant in healthy subjects?
Co-administration of the weak CYP3A4 inhibitor ticagrelor with fazamorexant does not result in clinically significant pharmacokinetic interactions, indicating no dosage adjustment is needed.
Answers are grounded in this paper and cite their sources.
Indicates no clinically significant interaction in healthy volunteers; leaves open effects in patients on ticagrelor.
Purpose Fazamorexant, a dual orexin receptor antagonist (DORA) targeting insomnia, demonstrated in vitro metabolism via CYP3A4. Thus, the effects of CYP3A4 inhibitors on the pharmacokinetics, safety, and tolerability of fazamorexant were investigated. Methods In this single-center, open-label, non-randomized, fixed-sequence study, 24 healthy subjects received a single oral dose of fazamorexant (20 mg) alone on D1, followed by a 6-day regimen of the CYP3A4 weak inhibitor ticagrelor (90 mg twice daily, Days 2 to 7) to reach steady state, with a second dose of fazamorexant co-administered on Day 6. Area under the plasma concentration–time curve from time zero to infinity (AUC0–inf), maximum plasma concentration (Cmax), time to Cmax (Tmax), and other relevant pharmacokinetic parameters were derived from plasma concentrations of fazamorexant collected at prespecified time points. Adverse events (AEs) were recorded. Results CYP3A4 weak inhibition by ticagrelor (90 mg, twice daily) increased the Cmax of fazamorexant by approximately 14% (90% confidence interval (CI): 100.92-129.07), whereas AUC0−t (90% CI: 86.44-125.58), AUC0− inf (90% CI: 85.60-124.53) and Tmax (P = 0.665) remained essentially unchanged. Fazamorexant, whether given alone or in combination with ticagrelor, was generally safe and well tolerated. Conclusion Overall, co-administration of CYP3A4 weak inhibitors with fazamorexant is not expected to result in clinically significant drug interactions, and no dosage adjustment is required when these agents are used concomitantly. Trial registration This trial was registered on the Drug Clinical Trial Registration and Information Disclosure Platform (registration number CTR20242889, accessible at https://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml?keywords=CTR20242889) on 5 August 2024, and on ClinicalTrials.gov (NCT06671470, accessible at https://clinicaltrials.gov/ct2/show/NCT06671470) on 31 October 2024. The ClinicalTrials.gov registration was retrospective.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied Healthy subjects (n=24). Fazamorexant and Ticagrelor co-administration vs. Fazamorexant 20 mg alone was evaluated on Maximum plasma concentration (Cmax) of fazamorexant (GMR 114.13%, 95% CI 100.92-129.07). Co-administration of ticagrelor with fazamorexant increased the Cmax of fazamorexant by approximately 14% without altering systemic exposure, indicating no clinically significant drug interaction.
Synapse has enriched 10 related papers. Consider them for comparative context: